Lycera

edit

Lycera isa preclinical-stage biopharma company focused on small molecule immunomodulators for the treatment of rheumatoid arthritis, lupus erythematosis and inflammatory bowel disease Lycera’s first-in-class drugs are designed to treat immune disorders. Lycera’s technology platforms include proprietary small molecules that modulate a target, which is central to cellular bioenergetics along with molecules that target the Th17 pathway.

Drugs that emerge from the Lycera pipeline will represent first-in-class agents that have the potential for first-in-class oral efficacy without the adverse effects of current standard-of-care antiproliferative and immunosuppressive agents.

Milestones

edit

• 
  Lycera received $36M in Series A funding. (5/5/09)
  Posted 6/24/09 at 11:25am

Videos

Screenshots

edit

Sources

1. Lycera Corp.: Series A $36M (onbiovc.com) [edit]